Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6XEQA)

• Drug Name: PF-610355 Drug Info
• Synonyms: PF-00610355; Beta 2 adrenoceptor agonist (asthma), Pfizer

Indication

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Discontinued in Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 11505444
  CAS Number: CAS 862541-45-5
  TTD Drug ID: DM6XEQA

Molecule-Related Drug Atlas

Drug(s) Targeting Adrenergic receptor beta-2 (ADRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indacaterol	DMQJHR7	Chronic obstructive pulmonary disease	CA22	Approved	[3]
Formoterol	DMSOURV	Allergic asthma	CA23.0	Approved	[4]
Salbutamol	DMN9CWF	Acute asthma	CA23	Approved	[5]
Arformoterol	DMYM974	Chronic obstructive pulmonary disease	CA22	Approved	[6]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[7]
Salmeterol	DMIEU69	Allergic asthma	CA23.0	Approved	[8]
Clenbuterol	DMCKYZ5	Chronic breathing disorder	7A4Z	Approved	[9]
Ritodrine	DM4V6RL	Premature labour	JB00	Approved	[10]
Olodaterol	DM62B78	Chronic obstructive pulmonary disease	CA22	Approved	[11]
Fenoterol	DMIP3ZV	Asthma	CA23	Approved	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-2 (ADRB2)	TT2CJVK	ADRB2_HUMAN	Agonist	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025582)
• [2] Inhalation by design: novel ultra-long-acting beta(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup. J Med Chem. 2010 Sep 23;53(18):6640-52.
• [3] Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
• [4] Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
• [5] Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
• [6] Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
• [7] Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
• [8] Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
• [9] Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [11] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [12] Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.